文献速递膀胱癌与上尿路尿路上皮癌

同一患者异时性与同时性上尿路及膀胱尿路上皮癌的表达分析

Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
PubMed 文献 · J Urol · 2021-04-21

本研究采用下一代测序比较同一患者异时性上尿路尿路上皮癌(UTUC)与膀胱尿路上皮癌(BUC)及同时性UTUC和BUC的基因表达。对40例未治疗患者的95个样本(UTUC=61,BUC=34)行全转录组RNA测序,无监督聚类分为基底样和管腔样两簇,Group 2肿瘤61.9%为基底样,而Groups 1、3、4多数为管腔样(80.6%、70.0%、69.6%,p=0.017)。87.5%的异时性肿瘤维持亚型归属。

要点

  • 异时性UTUC-BUC中多数继发于BUC的mUTUC呈基底样表达。
  • 同时性和初始UTUC肿瘤多呈管腔样表达。
  • 87.5%的异时性肿瘤维持初始肿瘤的分子亚型。

核心结论

  • 同一患者异时性UTUC-BUC基因表达分析提示多数BUC后发生的mUTUC更呈基底样,而同时性和初始UTUC呈管腔样。
  • 异时性肿瘤无论时间顺序或解剖起源,大多维持初始肿瘤的分子亚型归属。

研究设计与样本

  • 连续未治疗同一患者UTUC和BUC样本经质控后从FFPE切片宏切割,分为4组:UTUC-异时性BUC、BUC-异时性UTUC、同时性UTUC-BUC、无BUC的UTUC。
  • 排除临床数据不足或组织学肿瘤纯度<30%的样本,行全转录组RNA测序,对95个样本(UTUC=61,BUC=34)来自40例未治疗患者进行分析。

主要发现

  • 无监督共识聚类将肿瘤分为2簇,分别富集BASE47基底样或管腔样基因表达。
  • Group 2肿瘤中61.9%为基底样,而Groups 1、3、4多数为管腔样(分别为80.6%、70.0%、69.6%,p=0.017)。
  • 基底样与管腔样基因表达差异与成纤维细胞和免疫细胞基因表达特征相关。
  • 87.5%的异时性肿瘤维持亚型归属。

临床怎么用

  • 对于BUC后发生的异时性UTUC,应关注其基底样分子特征可能带来的临床行为差异。
  • 分子亚型在异时性肿瘤中高度保守,提示初始肿瘤的亚型信息可能指导后续UTUC的风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We compared upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) in same-patient metachronous UTUC and synchronous UTUC and BUC using next-generation sequencing. MATERIALS AND METHODS: Consecutive untreated same-patient samples of UTUC and BUC were macrodissected from unstained formalin-fixed, paraffin-embedded slides after quality control. Samples were divided into 4 groups: 1) UTUC-metachronous BUC, 2) BUC-metachronous UTUC, 3) synchronous UTUC-BUC, 4) UTUC without BUC. Exclusions were inadequate clinical data or histological tumor purity <30%. Whole transcriptome RNA sequencing was performed. After quality assessment, gene expression clusters using unsupervised hierarchical consensus clustering and correlation with pertinent clinicopathologic variables, a prior RNASeq data set and other published data were performed. RESULTS: RNAseq was performed on 95 samples (UTUC=61, BUC=34) from 40 untreated patients. Unsupervised consensus clustering segregated the tumors into 2 clusters that were enriched with BASE47 basal-like or luminal-like gene expression. Almost two-thirds (61.9%) of Group 2 tumors were basal-like, while the majority of Groups 1, 3, 4 (80.6%, 70.0% and 69.6%, respectively) were luminal-like (p=0.017). Further analyses revealed that the differences in basal-like and luminal-like gene expression were associated with differential fibroblast and immune cell gene expression signatures. In all, 87.5% of metachronous tumors maintained subtype membership. CONCLUSIONS: Gene expression analysis of same-patient metachronous UTUC-BUC suggests that the majority of mUTUC developing after BUC appear more basal-like, while synchronous and initial UTUC tumors appear luminal-like. Metachronous tumors largely maintain molecular subtype membership of the initial tumor regardless of chronologic development or anatomical origin.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Petros FG, Choi W, Qi Y, et al. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021. PMID: 33881933. doi:10.1097/JU.0000000000001788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。